Skip to main content
Top

Discover Oncology

Issue 3/2013

Content (7 Articles)

Editorial

Updates from the Editors

Carol A. Lange, Susan E. Hankinson, Wayne D. Tilley

Original Paper

GATA3 Mutations Found in Breast Cancers May Be Associated with Aberrant Nuclear Localization, Reduced Transactivation and Cell Invasiveness

Katherine U. Gaynor, Irina V. Grigorieva, Michael D. Allen, Christopher T. Esapa, Rosemary A. Head, Preethi Gopinath, Paul T. Christie, M. Andrew Nesbit, J. Louise Jones, Rajesh V. Thakker

Original Paper

Genomic Signatures of Pregnancy-Associated Breast Cancer Epithelia and Stroma and their Regulation by Estrogens and Progesterone

Djuana M. E. Harvell, Jihye Kim, Jenean O’Brien, Aik-Choon Tan, Virginia F. Borges, Pepper Schedin, Britta M. Jacobsen, Kathryn B. Horwitz

Original Paper

Altered PTEN, ATRX, CHGA, CHGB, and TP53 Expression Are Associated with Aggressive VHL-Associated Pancreatic Neuroendocrine Tumors

Allison B. Weisbrod, Lisa Zhang, Meenu Jain, Stephanie Barak, Martha M. Quezado, Electron Kebebew

Original Paper

Response of Human Pancreatic Cancer Cell Xenografts to Tetraiodothyroacetic Acid Nanoparticles

Murat Yalcin, Hung-Yun Lin, Thangirala Sudha, Dhruba J. Bharali, Ran Meng, Heng-Yuan Tang, Faith B. Davis, Steven C. Stain, Paul J. Davis, Shaker A. Mousa

Special Feature

Translational Highlights

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine